BR0014861A - Viral particles with exogenous internal epitopes - Google Patents
Viral particles with exogenous internal epitopesInfo
- Publication number
- BR0014861A BR0014861A BR0014861-0A BR0014861A BR0014861A BR 0014861 A BR0014861 A BR 0014861A BR 0014861 A BR0014861 A BR 0014861A BR 0014861 A BR0014861 A BR 0014861A
- Authority
- BR
- Brazil
- Prior art keywords
- viral particles
- expression
- viruses
- exogenous
- epitopes
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8202—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by biological means, e.g. cell mediated or natural vector
- C12N15/8203—Virus mediated transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
- C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
- C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18711—Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- C12N2760/18722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"PARTìCULAS VIRAIS COM EPìTOPOS INTERNOS EXóGENOS". A presente invenção refere-se à expressão de peptídeos em partículas virais e mais particularmente à expressão de peptídeos no interior do capsídeo viral. São descritos métodos para modificar os vírus de forma que os epítopos exógenos são expressos no interior do capsídeo viral. Os vírus que podem ser modificados incluem os vírus de RNA de filamento (+), especialmente os vírus vegetais de RNA de filamento (+) tal como o vírus mosáico do feijão-de-corda. A expressão interna é especialmente útil para a expressão de epítopos hidrofóbicos. As partículas virais modificadas também encontram uso como vacinas e como tais são capazes de ativar uma resposta imunológica."VIRAL PARTICLES WITH EXOGENOUS INTERNAL EPITOS". The present invention relates to the expression of peptides in viral particles and more particularly to the expression of peptides within the viral capsid. Methods for modifying viruses are described so that exogenous epitopes are expressed within the viral capsid. Viruses that can be modified include filament RNA viruses (+), especially vegetable filament RNA viruses (+) such as the arabica bean virus. Internal expression is especially useful for the expression of hydrophobic epitopes. The modified viral particles also find use as vaccines and as such are able to activate an immune response.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9924352.9A GB9924352D0 (en) | 1999-10-14 | 1999-10-14 | Methods,compositions and applications relating to the generation of novel plant viral particles |
PCT/US2000/028430 WO2001027282A1 (en) | 1999-10-14 | 2000-10-13 | Plant virus particles with exogenous internal eitopes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0014861A true BR0014861A (en) | 2002-07-16 |
Family
ID=10862753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0014861-0A BR0014861A (en) | 1999-10-14 | 2000-10-13 | Viral particles with exogenous internal epitopes |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP1235910A1 (en) |
JP (1) | JP2003534771A (en) |
KR (1) | KR100880477B1 (en) |
CN (2) | CN101591647A (en) |
AR (1) | AR026066A1 (en) |
AU (1) | AU785020B2 (en) |
BR (1) | BR0014861A (en) |
CA (1) | CA2387626A1 (en) |
CO (1) | CO5280142A1 (en) |
CZ (1) | CZ20021303A3 (en) |
GB (1) | GB9924352D0 (en) |
IL (1) | IL149077A0 (en) |
MX (1) | MXPA02003789A (en) |
PL (1) | PL354933A1 (en) |
WO (1) | WO2001027282A1 (en) |
ZA (1) | ZA200202815B (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1409551A4 (en) * | 2001-06-21 | 2004-10-13 | Uab Research Foundation | Chimeric capsid proteins and uses thereof |
US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
JP4953570B2 (en) | 2002-07-05 | 2012-06-13 | フォリア バイオテック インコーポレイテッド | Adjuvant virus particles |
WO2006041933A2 (en) | 2004-10-05 | 2006-04-20 | Diversa Corporation | Improved vaccines |
WO2007053188A2 (en) * | 2005-06-01 | 2007-05-10 | Dow Global Technologies, Inc. | Production of multivalent virus like particles |
EP1909829A4 (en) * | 2005-07-19 | 2009-11-11 | Dow Global Technologies Inc | Recombinant flu vaccines |
WO2009014782A2 (en) * | 2007-04-27 | 2009-01-29 | Dow Global Technologies Inc. | Improved production and in vivo assembly of soluble recombinant icosahedral virus-like particles |
WO2013003353A2 (en) * | 2011-06-30 | 2013-01-03 | Stc.Unm | Plasmids and methods for peptide display and affinity-selection on virus-like particles of rna bacteriophages |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9108386D0 (en) * | 1991-04-19 | 1991-06-05 | Agricultural Genetics Co | Modified plant viruses as vectors |
GB9712282D0 (en) * | 1997-06-12 | 1997-08-13 | Innes John Centre Innov Ltd | Epitope presentation system |
-
1999
- 1999-10-14 GB GBGB9924352.9A patent/GB9924352D0/en not_active Ceased
-
2000
- 2000-10-13 IL IL14907700A patent/IL149077A0/en unknown
- 2000-10-13 CN CNA2009101426265A patent/CN101591647A/en active Pending
- 2000-10-13 CZ CZ20021303A patent/CZ20021303A3/en unknown
- 2000-10-13 CA CA002387626A patent/CA2387626A1/en not_active Abandoned
- 2000-10-13 JP JP2001530485A patent/JP2003534771A/en active Pending
- 2000-10-13 CN CNA008167532A patent/CN1471580A/en active Pending
- 2000-10-13 EP EP00972153A patent/EP1235910A1/en not_active Withdrawn
- 2000-10-13 BR BR0014861-0A patent/BR0014861A/en not_active Application Discontinuation
- 2000-10-13 WO PCT/US2000/028430 patent/WO2001027282A1/en active Application Filing
- 2000-10-13 MX MXPA02003789A patent/MXPA02003789A/en unknown
- 2000-10-13 KR KR1020027004778A patent/KR100880477B1/en not_active IP Right Cessation
- 2000-10-13 PL PL00354933A patent/PL354933A1/en unknown
- 2000-10-13 AU AU10852/01A patent/AU785020B2/en not_active Ceased
- 2000-10-17 CO CO00078905A patent/CO5280142A1/en not_active Application Discontinuation
- 2000-10-17 AR ARP000105455A patent/AR026066A1/en unknown
-
2002
- 2002-04-10 ZA ZA200202815A patent/ZA200202815B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR026066A1 (en) | 2002-12-26 |
CA2387626A1 (en) | 2001-04-19 |
WO2001027282A1 (en) | 2001-04-19 |
MXPA02003789A (en) | 2002-09-30 |
AU1085201A (en) | 2001-04-23 |
KR20020040868A (en) | 2002-05-30 |
GB9924352D0 (en) | 1999-12-15 |
KR100880477B1 (en) | 2009-01-28 |
JP2003534771A (en) | 2003-11-25 |
IL149077A0 (en) | 2002-11-10 |
CN101591647A (en) | 2009-12-02 |
CN1471580A (en) | 2004-01-28 |
AU785020B2 (en) | 2006-08-24 |
CO5280142A1 (en) | 2003-05-30 |
CZ20021303A3 (en) | 2002-10-16 |
PL354933A1 (en) | 2004-03-22 |
WO2001027282A8 (en) | 2001-08-16 |
EP1235910A1 (en) | 2002-09-04 |
ZA200202815B (en) | 2003-08-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT1294893E (en) | MODIFICATION OF HEPATITIS B NUCLEAR ANTIGEN | |
BR0014171A (en) | Composition | |
EA200900784A1 (en) | VACCINES INCLUDING ANTIGENS FROM FOUR STRAINS OF THE INFLUENZA VIRUS | |
EP0667786A4 (en) | Retro-, inverso-, and retro-inverso synthetic peptide analogues. | |
IL153290A0 (en) | Assembly of wild-type and chimeric influenza virus-like particles (vlps) | |
AU2684792A (en) | Porcine reproductive respiratory syndrome vaccine and diagnostic | |
ATE270342T1 (en) | ENDOSOMOLYTIC PARTICLES | |
ES2035818T3 (en) | DELETION MUTANTS OF TIMIDIN-KINASA FROM HERPES BOVINE-1 VIRUSES, VACCINES AGAINST INFECTIOUS BOVINE RHINOTRAQUEITIS AND METHODS FOR THEIR PRODUCTION AND USE. | |
EA200801756A1 (en) | ANTIGRIPOPOSIC VACCINES CONTAINING HEMAGGLUTININ AND PROTEINS OF MATRIX | |
MXPA02002483A (en) | Vaccine against hbv and hpv. | |
BR0014861A (en) | Viral particles with exogenous internal epitopes | |
IL101780A0 (en) | Recombinant avipox virus,the culture of cells infected with this virus and vaccines for poultry derived from this virus | |
NZ518999A (en) | Vaccine compositions | |
BR0015740A (en) | Membrane virus host range mutations and their use as vaccine substrates | |
ES2061603T3 (en) | VIRAL MUTANTS OF INFECTIOUS BOVINE RHINOTRACHEITIS, VACCINES THAT CONTAIN THEM, METHODS FOR THE PRODUCTION OF THE SAME AND METHODS FOR THE USE OF THE SAME. | |
OA09653A (en) | Rubella peptides | |
ATE228568T1 (en) | HERPES VIRUS PARTICLE PREPARATION AND VACCINE | |
DE60330795D1 (en) | VACCINE AGAINST WEST NILE VIRUS | |
Mordhorst | Quantitation of the infectivity for cynomolgus monkeys of egg-grown inclusion conjunctivitis virus. A comparison of the clinical course of the experimental disease, the appearance of inclusion bodies and the regular recovery of the viral agent | |
HUP0002374A2 (en) | Recombinant equine herpesvirus type 1 (ehv-1) comprising a dysfunctional gene 71 region and use thereof as a vaccine | |
TH58564B (en) | Virus particles with epitope inside from external sources. | |
ATE126702T1 (en) | METHOD FOR PRODUCING VACCINES AGAINST RNA VIRUS. | |
Xiao et al. | Kinetics of antiviral state in cells activated by interferons in vitro | |
ES2065254B1 (en) | PEPTIDES AND SYNTHETIC VACCINES AGAINST CANINE PARVOVIRUSES AND OTHER RELATED VIRUSES. | |
WO2002078621A3 (en) | Replication-competent recombinant virus and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B11E | Dismissal acc. art. 34 of ipl - requirements for examination incomplete | ||
B11T | Dismissal of application maintained [chapter 11.20 patent gazette] |